多替拉韦方案治疗HIV-2感染:印度西部回顾性观察研究
免疫学有效率约91.6%–92%,病毒学有效率(HIV-2 VL<100 copies/mL)约85.7%–89.6%,中位CD4计数在6、12、18个月分别增加29、101、72 cells/mm3。多替拉韦耐受良好,对初治和经治HIV-2感染者均有效。
要点
- 多替拉韦方案对初治和经治HIV-2感染者免疫学有效率约91.6%–92%。
- 病毒学有效率(HIV-2 VL<100 copies/mL)约85.7%–89.6%。
- 中位CD4计数在6、12、18个月分别增加29、101、72 cells/mm3。
核心结论
- 多替拉韦耐受良好,在印度西部大型HIV-2队列中对初治和经治感染者均显示免疫学、病毒学和临床有效性。
- 基于多替拉韦的抗逆转录病毒治疗是HIV-2感染者的优良选择。
研究设计与样本
- 回顾性观察性研究,在印度西部两家诊所进行病历回顾。
- 主要目标为评估免疫学有效性,即绝对CD4计数较基线下降不超过30%。
- 通过拟合混合效应模型评估绝对CD4计数变化。
主要发现
- 免疫学有效率(95%CI)在所有、经治和初治人群中分别为91.9%(82.4%-96.5%)、92%(81.1%-96.8%)和91.6%(64.6%-98.5%)。
- 中位绝对CD4计数变化在6、12、18个月分别为+29 cells/mm3、+101 cells/mm3和+72 cells/mm3。
- 病毒学有效率(HIV-2 VL<100 copies/mL)(95%CI)在所有、经治和初治人群中分别为88.8%(74.6%-95%)、89.6%(73.6%-96.4%)和85.7%(48.6%-97.4%)。
- 记录到3例临床事件:脊柱结核、复发性非霍奇金淋巴瘤和单纯疱疹病毒性视网膜炎。
- 1例报告自限性嗜睡。
关键数值与推荐
- 免疫学有效性定义为绝对CD4计数较基线下降不超过30%。
- 病毒学有效性定义为HIV-2病毒载量<100 copies/mL。
临床怎么用
- 对于HIV-2感染者,可考虑使用基于多替拉韦的抗逆转录病毒治疗方案。
- 治疗中需监测CD4计数和HIV-2病毒载量以评估免疫学和病毒学应答。
局限性
- 回顾性观察性设计。
- 病毒学应答仅在部分个体中评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Data on the use of dolutegravir for treatment of HIV-2 infection are limited. OBJECTIVES: To assess the effectiveness of dolutegravir in people living with HIV-2 (PLHIV-2). METHODS: A retrospective chart review was performed in two clinics in Western India. PLHIV-2 initiated on dolutegravir-based regimens were included. Response to treatment in both treatment-naive (TN) and treatment-experienced (TE; substitution and not in the context of failure) was assessed by CD4 counts and HIV-2 viral load (VL) in a proportion of individuals. The primary objective was to assess immunological effectiveness (absence of a drop in absolute CD4 counts by more than 30% of baseline). Change in absolute CD4 counts was assessed by fitting a mixed-effects model. RESULTS: Sixty-two PLHIV-2 treated with dolutegravir were included. The immunological effectiveness rates (95% CI) were 91.9% (82.4%-96.5%), 92% (81.1%-96.8%) and 91.6% (64.6%-98.5%) amongst all, TE and TN individuals, respectively. Median change in absolute CD4 counts at 6, 12 and 18 months were +29 cells/mm3, +101 cells/mm3 and +72 cells/mm3, respectively. The virological effectiveness rates (HIV-2 VL <100 copies/mL) (95% CI) for all, TE and TN individuals were 88.8% (74.6%-95%), 89.6% (73.6%-96.4%) and 85.7% (48.6%-97.4%), respectively. Three clinical events were documented: spinal tuberculosis, relapsed non-Hodgkin's lymphoma and herpes simplex virus retinitis. One individual reported self-limiting somnolence. CONCLUSIONS: Dolutegravir was well tolerated and associated with immunological, virological and clinical effectiveness in both TN and TE PLHIV-2 in a large cohort from Western India. Dolutegravir-based ART is an excellent option for treatment of individuals with HIV-2 infection.
引用
- Pujari S, Patel A, Gaikwad S, et al. Effectiveness of dolutegravir-based antiretroviral treatment for HIV-2 infection: retrospective observational study from Western India. J Antimicrob Chemother. 2020. PMID: 32277827. doi:10.1093/jac/dkaa112
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。